1. Driver Mutations in Non-small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Mutations in Non-Small Cell Lung Cancer
Epidemiological studies have demonstrated a strong association between tobacco use and lung cancer; however, the genetic targets of these carcinogens and the role of other environmental agents in this process have yet to be defined. We examined the contribution of alcohol use and cigarette smoking to p53 gene mutations in patients with non-small cell lung cancer. Mutations of the p53 gene were ...
متن کاملOncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
BACKGROUND Oncogenic driver mutations are responsible for the initiation and maintenance of non-small-cell lung cancer (NSCLC). Elucidation of driver mutation occurrence in NSCLC has important clinical implications. PATIENTS AND METHODS NSCLC at various clinical stages were studied for their oncogenic mutations and their association with patients' disease-free survival (DFS). RESULTS Of 488...
متن کاملThe Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer.
A previously healthy, 30-year-old Filipino woman presented to an emergency department with complaints of shortness of breath and mild cough. She denied constitutional symptoms, such as night sweats, fevers, loss of appetite, or weight loss. Additional investigation revealed bilateral pleural and pericardial effusions with no obvious lung lesions or masses. The pericardial fluid was drained and ...
متن کاملEGFR mutations in non-small-cell lung cancer.
The epidermal growth factor receptor (EGFR) family members seem to play a critical role in lung tumourigenesis and are overexpressed in 40-80% of non-small cell lung carcinoma (NSCLC) tumours. EGFR activation results in a series of downstream signaling events that mediate cancer cell growth, proliferation, motility, adhesion, invasion, apoptosis inhibition and metastasis as well as resistance t...
متن کاملBRAF-mutations in non-small cell lung cancer.
OBJECTIVES Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. MATERIAL AND METHODS NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai Zasshi
سال: 2014
ISSN: 0021-5384,1883-2083
DOI: 10.2169/naika.103.1355